Pure Global
NCT06054594

Resistance Training and Cardiometabolic Risk

Resistance Training and Cardiometabolic Risk in Women With Metabolically Healthy and Unhealthy Obesity
Université du Québec a Montréal·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metabolic Syndrome
Drug/Device/Intervention
Resistance exercise
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Université du Québec a Montréal
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2009
End date
Jun 09, 2011
Enrollment
51 participants
Primary outcome

Insulin resistance (IR)

Summary

Little is known on the effects of resistance training (RT) alone in individuals with
 metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO). The present
 study aimed to examine the impact of RT on body composition, physical performance,
 lipid-lipoprotein profile, inflammation, and glucose-insulin homeostasis in 51 sedentary,
 postmenopausal women categorized as MHO vs MUHO, according to the Karelis and Rabasa- Lhoret
 classification or a single-phenotype adiposopathy approach (the plasma adiponectin (A)/leptin
 (L) ratio). Participants followed a 4-month weekly RT program of 3 non-consecutive days of 6
 exercises of major muscle groups (3 sets of 10 repetitions at 80% 1-RM).

ICD-10 classifications
Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06054594
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06054594 through Pure Global AI's free database. This phase not specified trial is sponsored by Université du Québec a Montréal and is currently Completed. The study focuses on Metabolic Syndrome. Target enrollment is 51 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.